Skip to content

It looks like we may have content for your preferred language. Would you like to view this page in English?

Orchid Can't Nix Roche Boniva Patent

By Samuel Howard, Law360
Loeb & Loeb LLP's Mark Waddell and Paula Colbath are noted as counsel for Hoffmann-La Roche Inc. in the pharmaceutical company's infringement actions against Orchid Chemicals & Pharmaceuticals Ltd. over Orchid's proposed generic version of the branded osteoporosis drug Boniva®. A federal judge rejected Orchid's bid to toss one of the five Boniva® patents asserted by Roche to prevent Orchid from marketing the generic drug.